This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Dermavant Sciences Ltd.
Dermavant Sciences Ltd., a leading biopharmaceutical company headquartered in Great Britain, focuses on developing innovative therapies for dermatological conditions. Founded in 2017, Dermavant has quickly established itself in the industry, particularly in the fields of psoriasis and atopic dermatitis, with a commitment to addressing unmet medical needs. The company’s flagship product, tapinarof, is a novel topical treatment that stands out for its unique mechanism of action and efficacy in managing skin disorders. Dermavant's dedication to research and development has positioned it as a key player in the dermatology market, with significant achievements in clinical trials and regulatory advancements. As it continues to expand its operational reach, Dermavant Sciences remains at the forefront of dermatological innovation, striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does Dermavant Sciences Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dermavant Sciences Ltd.'s score of 43 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dermavant Sciences Ltd., headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Organon & Co., which may influence its climate commitments and reporting practices. As part of its corporate family relationship, Dermavant's climate initiatives and performance metrics are likely aligned with those of Organon & Co. However, specific reduction targets or achievements have not been disclosed for Dermavant. The absence of documented reduction initiatives or Science-Based Targets (SBTi) suggests that the company may still be in the early stages of formalising its climate strategy. In the context of the broader industry, it is essential for companies like Dermavant to establish clear climate commitments and reduction targets to contribute effectively to global climate goals. As the landscape of corporate sustainability evolves, stakeholders will be looking for more transparency and accountability in emissions reporting and climate action from Dermavant Sciences Ltd.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dermavant Sciences Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
